Lishi Pharmaceutical: The drug Potassium Chloride Sustained-release Tablets has been submitted for market approval application.

Li Sheng Pharmaceutical announced that recently, the company has received the "Drug Registration Certificate" for the 0.5g specification of potassium chloride sustained-release tablets and the "Drug Registration Certificate" for the 0.6g specification of potassium chloride sustained-release tablets issued by the National Medical Products Administration. The above-mentioned drugs have been approved for marketing authorization.